Results 181 to 190 of about 28,931 (239)

Effects of danazol, gonadotropin-releasing hormone agonist, and a combination of danazol and gonadotropin-releasing hormone agonist on experimental endometriosis

American Journal of Obstetrics and Gynecology, 1990
Effects of danazol, gonadotropin-releasing hormone agonist (leuprolide), and danazol-leuprolide combination on experimental endometriosis were evaluated in female rats. A complete resorption of the fluid and a marked decrease in the volume of endometrium autotransplanted under the renal capsule were found after castration (1.4 +/- 0.1 mm3 in castrated,
M, Sakata, N, Terakawa, T, Mizutani, O, Tanizawa, K, Matsumoto, N, Terada, K, Sudo   +6 more
exaly   +3 more sources

Emerging gonadotropin-releasing hormone agonists

Expert Opinion on Emerging Drugs, 2011
Gonadotropin-releasing hormone agonist analogs (GnRHa) are peptides that mimic the action of gonadotropin-releasing hormone (GnRH) and are used to suppress subsequent sex steroid production. Although the analogs are a rather defined group of drugs, there have been developments in the past decades and there is still ample room for improvement.
Daniel Alexander, Beyer, Feriel, Amari, Marc, Thill, Askan, Schultze-Mosgau, Safaa, Al-Hasani, Klaus, Diedrich, Georg, Griesinger   +6 more
openaire   +2 more sources

Gonadotropin-releasing hormone agonists and the skeleton

Fertility and Sterility, 1992
To review and evaluate published studies that have assessed the effect on the skeleton of treatment with gonadotropin-releasing hormone agonists (GnRH-a). The effects on bone biochemistry and bone density are presented.Major studies reporting on bone and GnRH-a use were identified through Excerpta Medica and Medline searches.Those that have reported on
Edward E. Wallach, Ignac Fogelman
openaire   +2 more sources

Superactive Gonadotropin-Releasing Hormone Agonists

Annual Review of Medicine, 1983
Superactive GnRH agonists represent a new class of pharmacologic agents that inhibit reproductive function in both men and women when administered chronically. These hormonal drugs are being tested extensively as both male and female contraceptive agents, as a treatment for prostate cancer, and as a new treatment for idiopathic precocious puberty ...
R S, Swerdloff, D, Heber
openaire   +2 more sources

Conversion of a gonadotropin-releasing hormone antagonist to an agonist

Nature, 1982
Gonadotropin-releasing hormone (pyroGlu1-His2-Trp3-Ser4-Tyr5-Gly6-Leu7-Arg8-Pro9-Gly10 amide, GnRH) stimulates pituitary luteinizing hormone (LH) release. An antagonist, D-pyroGlu1-D-Phe2-D-Trp3-D-Lys6-GnRH (GnRH-Ant), binds to the pituitary GnRH receptor and inhibits GnRH-stimulated (10−9 M) gonadotropin release from pituitary cultures (IC50 = 2 × 10 ...
P M, Conn, D C, Rogers, J M, Stewart, J, Niedel, T, Sheffield   +4 more
openaire   +2 more sources

Gonadotropin-Releasing Hormone Agonists for Endometriosis

New England Journal of Medicine, 2008
A 36-year-old woman with a presumptive diagnosis of endometriosis presents with long-standing pelvic pain that is not relieved by means of oral contraceptives or medroxyprogesterone. Treatment with a gonadotropin-releasing hormone agonist is recommended.
openaire   +3 more sources

Endometriosis: treatment with gonadotropin-releasing hormone agonist Buserelin

Fertility and Sterility, 1989
Fifty-one women with pelvic endometriosis were treated with the gonadotropin-releasing hormone agonist (GnRHa) Buserelin (Hoechst Holland N.V., Amsterdam, The Netherlands) 300 micrograms three times a day intranasally for 6 months. Forty-nine women completed treatment; 42 were available for 6 months of follow-up following treatment.
FRANSSEN, AMHW, KAUER, FM, CHADHA, DR, ZIJLSTRA, JA, ROLLAND, R   +4 more
openaire   +3 more sources

Treatment of Hirsutism with a Gonadotropin-Releasing Hormone Agonist (Nafarelin)∗

The Journal of Clinical Endocrinology & Metabolism, 1986
GnRH analogs inhibit the secretion of gonadotropins and, therefore, that of estrogens and androgens of ovarian origin. The purpose of this study was to investigate the use of one superactive agonistic GnRH analog, nafarelin, in the treatment of hirsutism. Six hirsute women were treated with nafarelin (1 000 micrograms/day) for 6 months.
J L, Andreyko, S E, Monroe, R B, Jaffe
openaire   +2 more sources

INTRANASAL GONADOTROPIN-RELEASING HORMONE AGONIST AS A CONTRACEPTIVE AGENT

The Lancet, 1979
The stimulatory luteinising hormone-releasing hormone (LRH) analogue D-Ser(TBU)6-EA10-LRH was administered intranasally once daily to twenty-seven regularly menstruating women to determine its efficacy as a contraceptive agent. Ovulation was inhibited during all but 2 of the 89 treatment months.
C, Bergquist, S J, Nillius, L, Wide
openaire   +2 more sources

Gonadotropin-releasing hormone agonists

Current Opinion in Obstetrics and Gynecology, 1991
GnRH agonist (GnRHa) medications are now routinely used by gynecologists, urologists, medical endocrinologists, and pediatric endocrinologists alike. GnRHa are frequently highly effective in diminishing pain derived from endometriotic lesions. Current US Food and Drug Administration approval limits GnRHa regimens to a 6-month course largely because of ...
openaire   +2 more sources